Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Parkview Regional Medical Center — Fort Wayne, Indiana
- Goshen Center for Cancer Care — Goshen, Indiana
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Indiana: - IU Health North Hospital — Carmel, Indiana
- Deaconess Clinic Downtown — Evansville, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Riley Hospital for Children — Indianapolis, Indiana
- Ascension Saint Vincent Indianapolis Hospital — Indianapolis, Indiana
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Indiana: - Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Riley Hospital for Children — Indianapolis, Indiana
Phase 3 Recruiting Industry
This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whos…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Indiana: - Franciscan Health — Indianapolis, Indiana
Phase 3 Recruiting Industry
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…
Sponsor: AbbVie
NCT ID: NCT05445778
Sites in Indiana: - Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 269110 — Indianapolis, Indiana
- St. Vincent Indianapolis Hospital /ID# 269107 — Indianapolis, Indiana
Phase 2, Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Indiana: - Community MD Anderson Cancer Center- East — Indianapolis, Indiana
- Community MD Anderson Cancer Center- South — Indianapolis, Indiana
- Community Health Network - MD Anderson — Indianapolis, Indiana
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Indiana: - Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Indiana: - Parkview Research Center at Parkview Regional Medical Center ( Site 0003) — Fort Wayne, Indiana
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in Indiana: - Indiana University — Indianapolis, Indiana
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Indiana: - Woodland Cancer Care Center — Michigan City, Indiana
- Reid Health — Richmond, Indiana
- Memorial Hospital of South Bend — South Bend, Indiana
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Indiana: - UChicago Medicine Northwest Indiana — Crown Point, Indiana
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Indiana: - IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Main Campus — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
- Saint Mary Medical Center — Hobart, Indiana
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…
Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Indiana: - Parkview Research Center /ID# 274338 — Fort Wayne, Indiana
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492 — Indianapolis, Indiana
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Indiana: - Site 0284 - Community Cancer Center North — Indianapolis, Indiana
- Site 0217 - St Vincent Hospital and Health Care Centers — Indianapolis, Indiana
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Indiana: - Parkview Research Center — Fort Wayne, Indiana
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 2 Recruiting Industry
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in Indiana: - Research Site — Muncie, Indiana
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Sponsor: Cybrexa Therapeutics
NCT ID: NCT06315491
Sites in Indiana: - Northwest Cancer Centers — Dyer, Indiana
Phase 1, Phase 2 Recruiting Industry
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…
Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Indiana: - Clinical Trial Site — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).
Sponsor: Nabil Adra
NCT ID: NCT04804007
Sites in Indiana: - Indiana University Melvin & Bren Simon Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Indiana: - UChicago Medicine - Northwest Indiana — Crown Point, Indiana
- Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
- Community Health Network, Inc — Indianapolis, Indiana
- Community Health Network, Inc. — Indianapolis, Indiana
- Community Health Network Investigational Drug Services — Indianapolis, Indiana
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Indiana: - Indiana University — Indianapolis, Indiana
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Indiana: - Indiana University — Indianapolis, Indiana